Market Overview

Barclays Analyst Pens Open Letter To Gilead Board And Management

Share:
Barclays Analyst Pens Open Letter To Gilead Board And Management
Related GILD
Gilead Looking To Buy Incyte? It Makes Sense
Wall Street's M&A Chatter From March 10-12

On Friday, Barclays analyst Geoff Meacham veered from his typical approach of addressing clients and chose to speak directly to management at Gilead Sciences, Inc. (NASDAQ: GILD). Meacham chose to structure his latest research note on the pharma giant as a letter to the company, which included five recommendations for ways the company could potentially boost its market valuation.

According to Meacham, market sentiment toward Gilead seems to be at a low point recently.

“The purpose of this letter isn’t to single out your company as one that has been mismanaged (it hasn’t); rather, it is to provide context for the current valuation and with five concluding recommendations, help carve a roadmap to a re-rating,” Meacham explained.

5-Step Process

Barclays believes Gilead management can be proactive by taking the following five steps:

    1. Consider transformational M&A deals outside of the company’s core businesses.
    2. Consider cutting costs in the hepatitis C business if the market continues to decline.
    3. Give more clarity on the potential impact of the HIV franchise by providing guidance.
    4. Consider taking a more aggressive approach to in-licensing/business development.
    5. Consider shifting focus away from capital return and more toward reinvesting in the business via M&A and other potential growth measures.

Like most pharma stocks, Gilead has had a rough go of it in the past year, with shares now down 21.9 percent.

Barclays remains optimistic, however. The firm maintains an Outperform rating and a $90 price target for the stock.

Related Link:

  • Here's Who's Getting A Tax Cut Under The New Healthcare Proposal (You're Probably Not Included)
  • Response To GOP Healthcare Bill Ranges From Tepid Support To Outright Opposition
  • Latest Ratings for GILD

    DateFirmActionFromTo
    Mar 2017UBSDowngradesBuyNeutral
    Feb 2017CitigroupDowngradesBuyNeutral
    Nov 2016Stifel NicolausInitiates Coverage OnBuy

    View More Analyst Ratings for GILD
    View the Latest Analyst Ratings

    Posted-In: Analyst Color Biotech Long Ideas Health Care Politics Analyst Ratings Movers Trading Ideas Best of Benzinga

     

    Related Articles (GILD)

    View Comments and Join the Discussion!